A clinical briefing for providers on Iyuzeh availability in 2026, including prescribing strategies, insurance navigation, and patient access tools.
If you're an ophthalmologist, optometrist, or primary care provider who prescribes Iyuzeh (preservative-free Latanoprost 0.005%), you've likely heard from patients who can't fill their prescriptions. This briefing covers the current availability landscape, prescribing implications, cost considerations, and tools to help your patients access this medication in 2026.
Iyuzeh (Thea Pharma Inc.) is the first and only preservative-free Latanoprost approved in the United States for the reduction of elevated intraocular pressure (IOP) in adults with open-angle glaucoma (OAG) or ocular hypertension (OHT). It was FDA-approved in November 2022 and commercially launched in October 2023.
As of early 2026, Iyuzeh is not on the FDA's drug shortage list. Supply from the manufacturer remains stable. However, patient access challenges persist due to limited retail pharmacy stocking, insurance coverage barriers, and the absence of a generic equivalent.
Iyuzeh is clinically equivalent to BAK-preserved Latanoprost in IOP reduction. The Phase 3 clinical trial demonstrated non-inferiority to Xalatan in patients with primary OAG or OHT. The key differentiator is the absence of benzalkonium chloride (BAK), which is significant for patients with:
The preservative-free, single-dose format also eliminates concerns about multi-dose bottle contamination and reduces the cumulative BAK burden in patients on multiple topical IOP-lowering agents.
One drop in the affected eye(s) once daily in the evening. The onset of IOP reduction occurs within 3–4 hours, with peak effect at 8–12 hours. Room temperature storage — no refrigeration required.
The primary access challenge is retail pharmacy stocking, not supply. Key factors:
Providers can help patients by directing them to Medfinder for Providers, which shows real-time pharmacy-level stock information and can reduce the number of patients calling your office about availability issues.
Most commercial plans and Medicare Part D plans have Iyuzeh on a non-preferred brand tier or require prior authorization. Common requirements include:
Thea Pharma offers several patient access programs:
Note: These programs are not available to patients enrolled in Medicare, Medicaid, TRICARE, or other federal/state programs.
When Iyuzeh is not accessible or covered, consider these alternatives based on the clinical scenario:
For patient-facing information on alternatives, see Alternatives to Iyuzeh.
No generic preservative-free Latanoprost is expected in the near term. As awareness of ocular surface health and BAK toxicity continues to grow, demand for Iyuzeh is likely to increase. Providers can anticipate:
Iyuzeh fills an important clinical niche as the only preservative-free Latanoprost. While not in formal shortage, access challenges are real and stem primarily from limited retail stocking and insurance barriers. Providers can meaningfully improve patient outcomes by proactively directing patients to Medfinder, PhilRx home delivery, and manufacturer savings programs at the time of prescribing — before the patient arrives at a pharmacy that doesn't carry it.
For patient-facing resources, share our guides on how to find Iyuzeh in stock and how to save money on Iyuzeh.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
